Previous close | 8.55 |
Open | 8.10 |
Bid | 8.20 |
Ask | 8.30 |
Strike | 37.50 |
Expiry date | 2023-12-15 |
Day's range | 8.10 - 8.20 |
Contract range | N/A |
Volume | |
Open interest | 549 |
Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.